Sep 13, 2022 / 02:35PM GMT
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director
I think we're ready. So good morning, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Really pleased to have Gilead with us here. We have Dan O'Day, who is the CEO; and Bill Grossman, who heads up oncology. I have to read the disclosure statement before we start. So please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures. So with that, why don't we jump into it. I thought maybe a good place to start is actually where I started with some of the other larger companies is sort of a couple of questions on some of the recent developments in D.C. Obviously, the Inflation Reduction Act, Bob Roadway has a different name for it, by the way. Maybe you have a different name if you want to share.
Daniel P. O'Day - Gilead Sciences, Inc. - Chairman & CEO
Gilead Sciences Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers